Skip to Main Content

Top of the morning to you, and a fine one, it is. Once again, clear blue skies and deliciously cool breezes are enveloping the Pharmalot campus as we greet another day. Unfortunately, we can gaze out the window only so long, though. So time to get cracking, as they say. There is much to be done. No doubt you can relate, so here are a few tidbits to help you on your journey, which we hope is a productive and safe one today. Meanwhile, please do keep us in mind if any secret dossiers or saucy tips can be passed along. Have a good one. …

AstraZeneca (AZN) could start profiting from its Covid-19 vaccine as soon as July 2021, according to a memo showing the drug maker can declare when it considers the pandemic to have ended, The Financial Times reports. The company previously said it would not profit from the vaccine “during the pandemic.” The memorandum outlines conditions of a deal signed in July between the drug maker and Fiocruz, a Brazilian public health institution, to produce at least 100 million vaccine doses, worth more than $300 million. The “Pandemic Period” could be extended beyond July 1, 2021, but only if the company “acting in good faith considers that the SARS-CoV-2 pandemic is not over.”


Regeneron Pharmaceuticals (REGN) has asked federal regulators to authorize its antibody treatment for Covid-19 for emergency use, Bloomberg News writes. President Trump received the antibody cocktail last Friday under a compassionate use program after becoming sick with Covid-19. Trump hailed the Regeneron treatment in a video posted on Twitter, saying he would authorize its emergency use and make it available to Americans for free. Read more about the “pugnacious pair” running Regeneron at STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!